In this study, researchers examined payer costs and out-of-pocket patient costs for anticancer biologic drugs compared with biosimilars following the passage of the Biologics Price Competition and ...

Phase 3 SURPASS-ET data support the expanded indication of ropeginterferon alfa-2b-njft as the first new FDA-approved essential thrombocythemia therapy in nearly 3 decades.

Investigators conducted a retrospective study to determine the association between new-onset metabolic syndrome during the first year after initiation of concurrent androgen deprivation therapy and an ...

In this nationally representative, cross-sectional analysis, researchers assessed whether socioeconomic status and health care access affected screening adherence among adults with a history of ...

In this study, researchers evaluated the incidence and timing of TRAEs, readmissions, and transfusions after hospital discharge in patients with melanoma who received lifileucel treatment.

FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk individuals.

Consistently reduced hazard for death, cardiovascular disease, and hypertension reported across three independent cohorts ...

In this study, researchers developed and evaluated a blood-based cell-free and exosomal miRNA panel for detecting early-stage CRC and advanced adenomas.

The phase 1b/2 ELEVATE study evaluated everolimus, an mTORC1 inhibitor, plus elacestrant, a next-generation, oral selective ER degrader, in adult patients with ER+/HER2- breast cancer.

Tumor treating fields have demonstrated efficacy and safety, especially in glioblastoma treatment, but clinical uptake ...

Researchers evaluated the real-world outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

In this analysis, researchers sought to assess the impact of the 21st Century Cures Act, which gave the FDA increased flexibility to accept a single pivotal trial as the basis for a novel drug ...